Metsera, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
MTSR
Metsera, INCJanus Henderson Group plc has reported a 3.1% beneficial ownership stake in Metsera, Inc. common stock through its various asset managers.
MTSR
Metsera, INCFMR LLC and Abigail P. Johnson have reported a complete divestment of their beneficial ownership in METSERA INC, reducing their stake to 0%.
MTSR
Metsera, INCJanus Henderson Group plc has reported a 5.1% beneficial ownership stake in METSERA, INC., held for investment purposes.
MTSR
Metsera, INCMetsera, Inc. has become a wholly-owned subsidiary of Pfizer Inc., with shareholders receiving $65.60 per share in cash and contingent value rights.
MTSR
Metsera, INCThe Vanguard Group has reported a 5.53% beneficial ownership stake in Metsera Inc., holding 5,824,993 shares of common stock as of September 30, 2025.
MTSR
Metsera, INCSCHEDULE 13G: Investment Group Discloses Significant Stake in Metsera, Inc., Holding Over 12% of Common Stock
A group of investors, including Validae Health, L.P. and key individuals, has disclosed beneficial ownership of 12.2% to 12.5% of Metsera, Inc.'s common stock as of March 31, 2025.
MTSR
Metsera, INCFMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 14.4% of METSERA INC's common stock as of March 31, 2025.
MTSR
Metsera, INCFMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a significant passive ownership stake of 10.5% in METSERA INC, totaling 11,058,496 shares of common stock.